Prostate Cancer - Results from #340

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis. April 7, 2022

ADXS31-142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer:  Open-Label Phase I/II KEYNOTE-046 Study. April 7, 2022

Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd? April 7, 2022

Impact of Music on Postoperative Pain, Anxiety, and Narcotic Use After Robotic Prostatectomy: A Randomized Controlled Trial. April 7, 2022

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. April 7, 2022

[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. April 6, 2022

Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients. April 6, 2022

Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study). April 6, 2022

Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations. April 6, 2022

Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK. April 6, 2022

Foundation Medicine and Collaborators to Share Scientific Advances at AACR22 Reinforcing the Power of Genomic Testing in Precision Cancer Care April 5, 2022

Phase 1b/2 Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. April 5, 2022

Value of the capsular enhancement sign on dynamic contrast-enhanced prostate multiparametric MRI for the detection of extracapsular extension. April 5, 2022

Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. April 5, 2022

Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. April 5, 2022

Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. April 5, 2022

T2 mapping for the characterization of prostate lesions. April 4, 2022

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. April 4, 2022

Impact of obesity on perioperative, functional and oncological outcomes after robotic-assisted radical prostatectomy in a high-volume center. April 4, 2022

Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy. April 4, 2022

Page 18 of 1232

email news signup